China NMPA Drug Inspection - Harbin Runhe Traditional Chinese Medicine Processing Plant - Privet

The National Medical Products Administration (NMPA) of China, through Announcement No. 48 of 2023 on September 28, 2023, identified 22 batches of drugs from 14 manufacturers that failed to meet regulatory standards. Inspections revealed significant quality control deficiencies across various products. For instance, Shaanxi Haitian Pharmaceutical Co., Ltd.'s Xuefu Zhuyu Tablets failed identification tests. Multiple companies, including Hebei Hushi Yubo Pharmaceutical Co., Ltd. and Harbin Runhe Traditional Chinese Medicine Processing Plant, produced Fried Jujube Seeds with non-compliant moisture content, appearance, identification, and content determination. Henan Hongri Kangrentang Pharmaceutical Co., Ltd.'s Danshen Formula Granules failed fingerprint analysis and content determination. Additionally, Heilongjiang Wangda Traditional Chinese Medicine Pieces Technology Co., Ltd. had issues with total ash content in Lycium chinense root bark, while several manufacturers like Hebei Guorentang Pharmaceutical Co., Ltd. produced Ligustrum lucidum with excessive moisture. These violations fall under the regulatory framework of the "Drug Administration Law of the People's Republic of China" and the 2020 edition of the Pharmacopoeia. The NMPA requires affected companies to implement immediate risk control measures, including suspending sales, recalling substandard products, investigating the root causes of non-compliance, and undertaking thorough rectification. Provincial authorities are also mandated to investigate suspected illegal activities and publicly disclose their findings.